6th Closed Expert Meeting of the Editorial Board
Professor Anthony Wierzbicki (Guy’s & St Thomas’ Hospitals, London, UK) provides a back to basics on cost-effectiveness analyses. Specifically, he highlights the uses and abuses of cost-effectiveness and quality-adjusted life year analyses in determining access to novel treatments. One of the key questions in cost-effectiveness…read more »
Professor Henry Ginsberg (University of Columbia, New York, USA) overviews the evolution of lipid guidelines to prevent cardiovascular disease highlighting the areas of contention between USA and Europe, and the place of PCSK9 inhibition.read more »
Professor Packard (University of Glasgow, UK) discusses how early signs of cardiac dysfunction/injury (such as troponin I, a biomarker of cardiomyocyte damage or stress) may help in identifying individuals at risk of cardiovascular events, with insights from the WOSCOPS study. Translating these insights to primary…read more »
What can we learn from Mendelian randomisation about the impact of lipid lowering on CVD and risk of dysglycaemia?
The design of Mendelian randomization studies, i.e. ‘naturally randomized trials’, is critical to anticipate results of randomised controlled trials in lipid lowering, as well as inform about potential adverse effects. Here Professor Brian Ference (Wayne State University School of Medicine, Detroit, USA) discusses how insights…read more »